Diagnos (ADK) AI Stock Analysis

• Market Cap: C$31.34M
• Dividend Yield: N/A
• Average Volume (3M): 237.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.03
• Revenue Growth: -35.15%
• EPS Growth: -6.59%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 78
• Industry: Healthcare Providers & Services
• EPS (TTM): -0.04
• Shares Outstanding: 101,082,980
• 10 Day Avg. Volume: 131,720
• 30 Day Avg. Volume: 237,320
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 198.36
• Price to Cash Flow (P/CF): -10.40
• P/FCF Ratio: 52.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Diagnos's overall stock score is significantly hampered by its poor financial performance, characterized by negative equity and reliance on external financing. While technical analysis indicates bearish trends, positive corporate events, such as FDA filings and financing, offer potential future opportunities but are not yet realized. The lack of earnings call data prevents further insights into management's outlook.

Diagnos Business Overview & Revenue Model

Company Description

Diagnos (ADK) is a technology company specializing in the development and commercialization of artificial intelligence (AI) solutions for healthcare diagnostics. The company operates primarily in the healthcare sector, providing advanced AI algorithms and software platforms that assist in the early detection and management of various health conditions, with a focus on diabetic retinopathy and cardiovascular diseases.

How the Company Makes Money

Diagnos makes money through the commercialization of its AI-powered diagnostic solutions, which are offered to healthcare providers, clinics, and hospitals. The company's revenue model includes licensing fees for the use of its proprietary software platforms and AI algorithms. Additionally, Diagnos may engage in partnerships and collaborations with healthcare institutions and technology companies to expand its market reach, which can also contribute to its revenue. These partnerships may involve joint ventures or collaborative research and development projects aimed at enhancing the efficacy and applicability of its diagnostic solutions.

Diagnos Financial Statement Overview

Summary

Diagnos faces severe financial challenges with consistent losses, negative equity, and reliance on external financing. The income statement shows deep operational inefficiencies and declining revenues, while the balance sheet and cash flow statements highlight solvency risks and cash flow deficits.

Income Statement

Diagnos has experienced significant challenges in its income statement with persistent negative gross profit and net income over the years. The TTM report shows a gross profit margin of -684.16% and a net profit margin of -2948.02%, indicative of severe operational inefficiencies and high costs relative to revenue. The revenue growth rate has also been negative, marking a concerning downward trend in sales. Overall, the company's profitability remains deeply negative, impacting its financial stability.

Balance Sheet

Diagnos's balance sheet reveals a highly leveraged position with a negative stockholders' equity of -$477,206 in the TTM. The debt-to-equity ratio is not calculable due to negative equity, highlighting significant financial risk. Additionally, the equity ratio is negative at -14.92%, indicating that liabilities exceed assets, further underscoring the company's precarious financial position. These factors reflect significant solvency concerns and potential risks in maintaining operations.

Cash Flow

Cash flow analysis shows consistent negative operating and free cash flows, with the TTM free cash flow at -$3,002,144. The operating cash flow to net income ratio is 0.80, suggesting cash flow issues relative to the net loss. While financing cash flow has been positive, it primarily reflects a reliance on external funding rather than operational success. This reliance on external financing presents a risk if funding sources become unavailable.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
127.40K	170.16K	438.83K	267.07K	331.52K	326.47K
	Gross Profit
-871.40K	35.80K	-418.30K	-347.53K	-473.45K	-759.37K
	EBIT
-1.25M	-2.69M	-2.55M	-2.02M	-2.71M	-2.88M
	EBITDA
-3.04M	-2.45M	-2.10M	-2.45M	-1.93M	-2.94M
	Net Income Common Stockholders
-3.76M	-3.12M	-2.61M	-2.05M	-3.38M	-3.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.82M	219.01K	920.91K	1.36M	1.87M	693.95K
	Total Assets
3.20M	663.79K	1.54M	1.95M	2.43M	1.21M
	Total Debt
3.29M	3.19M	1.19M	471.68K	337.55K	5.52M
	Net Debt
3.22M	2.97M	764.86K	112.29K	-232.89K	5.38M
	Total Liabilities
3.67M	3.72M	1.66M	818.19K	614.78K	6.29M
	Stockholders Equity
-477.21K	-3.05M	-113.51K	1.13M	1.82M	-5.08M
Cash Flow		Free Cash Flow
-3.00M	-2.16M	-2.07M	-1.40M	-2.66M	-2.36M
	Operating Cash Flow
-2.99M	-2.15M	-2.04M	-1.36M	-2.64M	-2.32M
	Investing Cash Flow
-2.56M	-14.02K	503.52K	262.93K	-759.98K	-96.47K
	Financing Cash Flow
5.52M	2.08M	1.60M	882.82K	3.83M	2.40M

Diagnos Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.33, and below the 200-day MA of 0.33, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.42 is Neutral, neither overbought nor oversold. The STOCH value of 30.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ADK.

Diagnos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
PTK	44 Neutral	$389.39M	―	-161.80%	―	-78.34%	-9.55%
ADK	31 Underperform	C$31.34M	―	366.78%	―	-35.15%	-6.59%

Diagnos Corporate Events

Diagnos Inc. Amends Convertible Debenture Terms

Diagnos Inc. has announced an amendment to the terms of its unsecured convertible debentures, extending the maturity date from March 1, 2025, to March 1, 2026, and increasing the interest rate from 8% to 10% for the extended period. This amendment is subject to acceptance by the TSX Venture Exchange and aims to adjust financial terms to better align with market conditions, potentially impacting investor relations and financial strategy.

Diagnos Inc. Seeks FDA Approval for AI-Driven CARA SYSTEM

Diagnos Inc. has announced its filing for FDA pre-market authorization for its AI-powered CARA SYSTEM, designed to assist in the early detection of various eye diseases. The company has partnered with ORA, a leading clinical research organization, to navigate the U.S. regulatory landscape, marking a significant step in its expansion strategy and enhancing its market visibility.

DIAGNOS Completes $2 Million Private Placement for AI Advancements

DIAGNOS Inc. announced the closing of a private placement, raising $2,014,610.70 through the issuance of 6,715,369 units at $0.30 each. The proceeds will support product development and commercialization of AI-based screening services, regulatory affairs, and general operations. Each unit includes a share and a warrant, with warrants exercisable at $0.40 within 18 months. The completion of this placement is subject to regulatory approvals, and securities issued are under a hold period until June 6, 2025.

DIAGNOS Closes $2 Million Private Placement to Boost AI Screening Services

DIAGNOS Inc. announced the closing of a non-brokered private placement, raising gross proceeds of $2,014,611 through the issuance of over 6.7 million units at $0.30 per unit. Each unit comprises one common share and one warrant, exercisable at $0.40 for 18 months. The funds will support the development and commercialization of AI-based screening services, regulatory affairs, and general operations. The placement is subject to regulatory approvals and all issued securities are under a statutory hold period until June 6, 2025.

DIAGNOS Secures $400,000 from Canadian Government for International Expansion

DIAGNOS announced receiving a financial contribution of up to $400,000 from the Canada Economic Development for Quebec Regions to support its international marketing strategy for the CARA project. This funding highlights the government’s recognition of DIAGNOS as a significant player in the Canadian economy, potentially enhancing its market position and expanding its global reach.

Diagnos to Highlight AI Innovations at The Microcap Conference 2025

Diagnos Inc. announced its participation in The Microcap Conference 2025, aiming to showcase its AI-driven medical detection technology and engage with investors. The event is viewed as a strategic opportunity to enhance investor relations, particularly with U.S. investors, and to highlight potential growth milestones, including partnerships and expected deployments in 2025.

DIAGNOS Engages OTB for Enhanced Market Visibility

DIAGNOS Inc. has engaged Outside The Box Capital Inc. (OTB) to provide marketing and promotional services, aiming to increase its public awareness. The agreement involves a CA$50,000 compensation for OTB, which will use digital marketing strategies, including social media, over a three-month period. This strategic move is expected to enhance DIAGNOS’s visibility in the market, subject to TSX Venture Exchange approval.